Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2025.153167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Sangyeon Won und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Medical Science, Graduate …. Hauptthemen laut MEDLINE: Cellular Senescence, Nuclear Proteins, DNA Damage, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Military Institute of Science and Technology, National Research Foundation of Korea.
Abstract (Originalsprache)
Cellular senescence is a stable growth arrest commonly triggered in cancer cells by chemotherapy or radiotherapy. Although therapy-induced senescence (TIS) initially suppresses tumor proliferation, the persistence of senescent cells can promote relapse and therapeutic resistance. Here, we identify Sestrin2 as a critical regulator of senescent cancer cell survival following DNA-damaging therapies. Sestrin2 expression is robustly induced in TIS cancer cells in a p53-dependent manner. Genetic depletion of Sestrin2 selectively impairs the viability of senescent, but not proliferating, cancer cells. Mechanistically, Sestrin2 knockdown amplifies SASP gene expression and NF-κB activation, leading to endoplasmic reticulum (ER) stress and apoptotic cell death. Importantly, Sestrin2 depletion consistently enhances the elimination of senescent cancer cells across diverse genotoxic therapies. These findings reveal a pivotal pro-survival role for Sestrin2 in TIS cancer cells and highlight its potential as a therapeutic target to improve the efficacy of DNA-damaging cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Medical Science, Graduate School of the Catholic University of Korea, Seoul, Republic of Korea;…
- Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Institute for Aging and Metabolic Diseases, College of Medicine, The Catholic University of Korea, Seoul, Repu…
Förderung
- Military Institute of Science and Technology
- National Research Foundation of Korea
Zitieren
APA
Won, S., Kim, M., Yang, S., Seo, J., Ko, M., Lee, E. K., & Jeong, S. M. (2026). Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.153167
Vancouver
Won S, Kim M, Yang S, Seo J, Ko M, Lee EK, et al. Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2025.153167
BibTeX
@article{Won2026,
author = {Won, Sangyeon and Kim, Minjoong and Yang, Seungyeon and Seo, Jiyoon and Ko, Minbeom and Lee, Eun Kyung and Jeong, Seung Min},
title = {Targeting Sestrin2 impairs survival of senescent cancer cells following DNA-damaging therapies},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2025.153167}
}
EUVIMED